Canada Pension Plan Investment Board Lowers Holdings in Illumina, Inc. (NASDAQ:ILMN)

Canada Pension Plan Investment Board lowered its position in Illumina, Inc. (NASDAQ:ILMN) by 9.1% during the 4th quarter, HoldingsChannel reports. The firm owned 413,492 shares of the life sciences company’s stock after selling 41,150 shares during the period. Canada Pension Plan Investment Board’s holdings in Illumina were worth $55,255,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Versant Capital Management Inc raised its holdings in shares of Illumina by 153.7% in the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new stake in Illumina in the fourth quarter valued at approximately $32,000. Assetmark Inc. raised its stake in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina during the fourth quarter valued at approximately $45,000. Finally, Lee Danner & Bass Inc. purchased a new position in Illumina in the 4th quarter worth approximately $48,000. Institutional investors own 89.42% of the company’s stock.

Illumina Trading Down 3.2 %

NASDAQ:ILMN opened at $71.21 on Friday. Illumina, Inc. has a 12 month low of $68.70 and a 12 month high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a 50-day moving average price of $84.61 and a 200-day moving average price of $120.40. The stock has a market cap of $11.27 billion, a price-to-earnings ratio of -9.27, a P/E/G ratio of 1.60 and a beta of 1.38.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Ratings Changes

ILMN has been the subject of a number of research analyst reports. Stephens reaffirmed an “overweight” rating and set a $156.00 price objective on shares of Illumina in a report on Tuesday, March 11th. Barclays dropped their price target on Illumina from $100.00 to $77.00 and set an “underweight” rating for the company in a research note on Thursday, April 10th. Royal Bank of Canada reduced their price objective on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a research report on Tuesday, April 8th. Citigroup dropped their target price on Illumina from $90.00 to $85.00 and set a “neutral” rating for the company in a research report on Monday, April 7th. Finally, HSBC lowered Illumina from a “buy” rating to a “hold” rating and set a $100.00 target price for the company. in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $138.70.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.